What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Tillett et al. Baseline characteristics and achievement of MDA at week 24 with IL23i guselkumab in bDMARD experienced patients. Pattern of joint (wrist vs shoulder/hand) and skin (scalp vs hand/foot) involvement, as well as male sex, predictive @RheumNow #EULAR2022 POS1051 https://t.co/lHOTgMWgMA
Richard Conway RichardPAConway
3 years 6 months ago
den Broeder et al. Follow-up to REDO study. Ultra-low dose RTX non-inferior for DAS28CRP. 1000mg 2.2 (2.0-2.4), 500mg 2.2 (2.1-2.4), 200mg 2.3 (2.2-2.5) (all given 6-monthly). Small effect by received dose though (0.15 per 1000mg) @RheumNow #EULAR2022 POS0652 https://t.co/hfSw9ndQpk
Richard Conway RichardPAConway
3 years 6 months ago
Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB
Dr. John Cush RheumNow
3 years 6 months ago
Video: What Patients Want and Are Willing to Risk with SLE
Dr. Kathryn Dao discusses abstract POS0086 at #EULAR2022 which looks at real life lupus patient preferences who are willing to undergo risk in order to get the treatment outcome that they desire.
https://t.co/kHZz5MrZi2 https://t.co/XRsoXHR1ce
Richard Conway RichardPAConway
3 years 6 months ago
Campaniello et al. Ultra-low dose RTX (500/1000mg once a year) vs low dose RTX (500/1000mg 6-monthly) for maintenance in AAV. Comparable relapse free survival 22.7% vs 21.2%, lower severe infection 10.5% vs 26.8% @RheumNow #EULAR2022 POS0837 https://t.co/uBgEmhLUzv
Richard Conway RichardPAConway
3 years 6 months ago
Prof McInnes @IainBMcInnes1 et al. IL23i guselkumab efficacy maintained irrespective of baseline characteristics of patients. I kind of wish in some of these studies that we would see big differences to help us select between agents! @RheumNow #EULAR2022 POS0072 https://t.co/zJWvpwcDkt
Janet Pope Janetbirdope
3 years 6 months ago
WIN-Lupus is no winner. Stopping #MMF or #Azathioprine after 2 to 3 yrs of well controlled #SLE is a loser due to more #lupus nephritis. Diff from RCT of MMF taper in remission pts. @RheumNow @eular_org #EULAR2022 https://t.co/Ut8uRonrNP
Richard Conway RichardPAConway
3 years 6 months ago
Dr Terrier @TerrierBen Mepolizumab gives clinical benefit in EGPA in terms of remission at week 36/48 and accrued remission. Benefit irrespective of presence of vasculitic features, ANCA status, clinical features, etc @RheumNow #EULAR2022 POS0836 https://t.co/GHwt1WNZEs
Richard Conway RichardPAConway
3 years 6 months ago
Adami et al Real world fracture prevention with osteoporosis meds. 30% lower risk with bisphosphonate, 60% denosumab, 90% teriparatide. Bisphosphonates only showed effect after 1 year. Not sure I buy it, very different to RCTs. @RheumNow #EULAR2022 OP0239 https://t.co/6qaYAVw73Q https://t.co/bNwWmxxSeF
Richard Conway RichardPAConway
3 years 6 months ago
Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc
David Liew drdavidliew
3 years 6 months ago
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
Richard Conway RichardPAConway
3 years 6 months ago
Amigues et al. Zoledronate related ONJ. French pharmacovigilance database. Rare with rheumatic (vs onc) use but higher than with risedronate or alendronate. Incidence 9.6 vs 2 vs 5.1 /100000 @RheumNow #EULAR2022 OP0240 https://t.co/SCYiyJF76S
Richard Conway RichardPAConway
3 years 6 months ago
Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8
Richard Conway RichardPAConway
3 years 6 months ago
Fornaro et al. GISEA registry. No effect of reduced eGFR<60 on drug survival HR 0.9 (95%CI 0.7-1.2) @RheumNow #EULAR2022 POS0634 https://t.co/TjjxgCCz0Z
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Poster Hall